IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
IRadimed CorporationNASDAQ: IRMD
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $7.89M rose 1226.4% year over year, ahead of the +72.2% change in trailing-twelve-month free cash flow. Sequentially, it rose 45.0% from the prior quarter. Over 3 fiscal years it compounded at +28.1% a year.
Context
- Free cash flow amounted to 20.5% of revenue in FY2025, down 3.6 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1226.4% holds above the trailing-twelve-month pace of +72.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 17.18M USD
- Year-over-year change
- -2.5%
- 4-year CAGR
- +13.1%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.18M | -2.5% |
| FY2024 | 2024-12-31 | 17.62M | +222.8% |
| FY2023 | 2023-12-31 | 5.46M | -33.2% |
| FY2022 | 2022-12-31 | 8.17M | -22.3% |
| FY2021 | 2021-12-31 | 10.52M | — |
Free Cash Flow vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's LTM Mar 2026 free cash flow of $24.1M is the 8th largest of the 11 companies compared; the peer median is $21.39M.
- Its year-over-year change of +72.2% is the 3rd highest of 11, against a peer median of -9.8%.
- Free cash flow amounts to 27.9% of revenue for IRMD, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $191.95M | -30.1% | — | 6.7% | |
| LTM Mar 2026 | $174.22M | -15.5% | +16.8% | 30.0% | |
| LTM Mar 2026 | $131.64M | +39.2% | +21.5% | 16.7% | |
| LTM Mar 2026 | $90.65M | -25.7% | -22.3% | 24.2% | |
| LTM Mar 2026 | $65.5M | +10.6% | — | 16.8% | |
CTEVClaritev Corporation | LTM Mar 2026 | $38.76M | -60.9% | — | 4.0% |
| LTM Mar 2026 | $26.47M | +449.9% | — | 12.9% | |
| LTM Mar 2026 | $24.1M | +72.2% | +28.1% | 27.9% | |
| LTM Sep 2026 | $16.31M | +471.7% | -57.2% | 6.1% | |
| LTM Mar 2026 | $10.12M | -60.2% | — | 0.6% | |
| LTM Mar 2026 | $3.64M | -4.1% | — | 0.4% | |
| Peer median (excluding IRMD) | $21.39M | -9.8% | -2.8% | 9.8% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M |
| Depreciation & Amortization | 1.41M | 670.67K | 765.18K | 817.66K | 1.17M |
| Deferred Income Tax | 523.61K | 57.1K | (1.17M) | (697.65K) | 0 |
| Stock-Based Compensation | 1.46M | 1.39M | 2.19M | 2.52M | 2.92M |
| Change in Working Capital | (1.58M) | (5.06M) | (5.91M) | 3.75M | (4.35M) |
| Accounts Receivables | (575.54K) | (8.24M) | 841.91K | 1.76M | (3.03M) |
| Inventory | (393.32K) | (1.31M) | (7.47M) | 3.13M | (1.38M) |
| Accounts Payables | 30.41K | 1.12M | (216.44K) | (861.62K) | (76K) |
| Other Working Capital | (637.72K) | 3.37M | 932.43K | (277.58K) | 135K |
| Other Non-Cash Items | 119.04K | 148.74K | 402.32K | (3.02K) | 2.73M |
| Operating Cash Flow | 11.26M | 10.04M | 13.47M | 25.62M | 24.95M |
| Capital Expenditures | (741.76K) | (1.87M) | (8.01M) | (8.01M) | (7.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 1.39M | 500K | 0 | 0 | 0 |
| Other Investing Activities | (259.43K) | (1.05M) | (566.66K) | (811.75K) | (656K) |
| Investing Cash Flow | 648.24K | (1.37M) | (8.01M) | (8.82M) | (8.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 29.62K | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | (12.56M) | (13.22M) | (13.68M) | (15.04M) |
| Other Financing Activities | 24.43K | (147.27K) | (433.6K) | (688.16K) | (2.56M) |
| Financing Cash Flow | 24.43K | (12.71M) | (13.66M) | (14.34M) | (17.6M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.93M | (4.04M) | (8.2M) | 2.47M | (1.08M) |
| Free Cash Flow | 10.52M | 8.17M | 5.46M | 17.62M | 17.18M |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.